Stifel Nicolaus Cuts Beta Bionics (NASDAQ:BBNX) Price Target to $25.00

Beta Bionics (NASDAQ:BBNX) had its price objective decreased by Stifel Nicolaus from $31.00 to $25.00 in a research note published on Wednesday, Marketbeat.com reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Piper Sandler reissued an “overweight” rating and issued a $32.00 price target (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Truist Financial dropped their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. TD Cowen started coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target for the company. Finally, Robert W. Baird set a $28.00 target price on Beta Bionics in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $26.64.

Beta Bionics Stock Down 1.2%

Shares of NASDAQ BBNX opened at $13.08 on Wednesday. The business has a fifty day simple moving average of $24.23 and a two-hundred day simple moving average of $22.56. The firm has a market cap of $575.91 million and a PE ratio of -2.99. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $32.71.

Insider Buying and Selling

In related news, insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the transaction, the insider directly owned 80,752 shares in the company, valued at $2,430,635.20. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the transaction, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 32,490 shares of company stock worth $960,835.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors and hedge funds have recently bought and sold shares of BBNX. GPS Wealth Strategies Group LLC increased its holdings in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares during the period. Strs Ohio acquired a new position in shares of Beta Bionics during the first quarter valued at $29,000. Ameritas Investment Partners Inc. boosted its position in shares of Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after buying an additional 1,863 shares during the period. Finally, Legal & General Group Plc lifted its holdings in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.